4.3 Article

Nonunions Treated With Autologous Preparation Rich in Growth Factors

Journal

JOURNAL OF ORTHOPAEDIC TRAUMA
Volume 23, Issue 1, Pages 52-59

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/BOT.0b013e31818faded

Keywords

bone graft; fracture fixation; growth factors; nonunion; platelets; percutaneous injection

Funding

  1. Basque and Spanish Governments

Ask authors/readers for more resources

Objectives: To evaluate the clinical safety and efficacy of using a biologic technology known as preparation rich in growth factors (PRGF) for the treatment of nonhypertrophic nonunion. Design: The design of the study was a retrospective case series. Setting: The private practice was in 2 centers. Patients: There were 15 patients with a total of 16 aseptic non-unions, 12 diaphyseal and 4 supracondylar, diagnosed as nonhypertrophic. The mean time since prior surgical treatment was 21 months (9-46 months). Intervention: Supracondylar and diaphyseal nonunions followed surgical fixation with condylar plating or intramedullary nailing, whereas a composite biomaterial created by mixing PRGF with bone allograft was applied. The area was then covered with autologous fibrin membranes. Stable nonunions were treated with repeated percutaneous injections of PRGF; this minimally invasive procedure was also applied if delayed healing was suspected after surgical treatment. Main Outcome Measurements: Radiographic union using radiographic views was taken in 2 planes. Clinical outcome evaluated pain, motion at the fracture site upon manual stress testing, and recovery of range of motion. Results: All nonunions treated operatively heated after a single procedure, even though additional PRGF had to be injected in 2 patients. Two of 3 stable nonunions achieved healing only after repeated percutaneous PRGF injections. The mean time from surgery and/or PRGF application to union was 4.9 months (2-8 months). Complications associated with the described procedure were not observed. Conclusion: This study, although uncontrolled, shows that PRGF technology is clinically safe and can enhance the healing of nonhypertrophic nonunions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available